Literature DB >> 11328818

Identification and characterization of S2V, a novel putative siglec that contains two V set Ig-like domains and recruits protein-tyrosine phosphatases SHPs.

Z Yu1, C M Lai, M Maoui, D Banville, S H Shen.   

Abstract

We describe the molecular cloning and characterization of S2V, a novel sialic acid binding immunoglobulin-like lectin. The cDNA of S2V encodes a type 1 transmembrane protein with four extracellular immunoglobulin-like (Ig-like) domains and a cytoplasmic tail bearing a typical immunoreceptor tyrosine-based inhibitory motif (ITIM) and an ITIM-like motif. A unique feature of S2V is the presence of two V-set Ig-like domains responsible for the binding to sialic acid, whereas all other known siglecs possess only one. S2V is predominantly expressed in macrophage. In vivo S2V was tyrosine-phosphorylated when co-expressed with exogenous c-Src kinase. Upon tyrosine phosphorylation, S2V recruits both Src homology 2 (SH2) domain-containing protein-tyrosine phosphatases SHP-1 and SHP-2, two important inhibitory regulators of immunoreceptor signal transduction. These findings suggest that S2V is involved in the negative regulation of the signaling in macrophage by functioning as an inhibitory receptor. When expressed in COS-7 cells, S2V was able to mediate sialic acid-dependent binding to human red blood cells, suggesting that S2V may function through cell-cell interaction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11328818     DOI: 10.1074/jbc.M102394200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  SIGLEC12, a human-specific segregating (pseudo)gene, encodes a signaling molecule expressed in prostate carcinomas.

Authors:  Nivedita Mitra; Kalyan Banda; Tasha K Altheide; Lana Schaffer; Teresa L Johnson-Pais; Joke Beuten; Robin J Leach; Takashi Angata; Nissi Varki; Ajit Varki
Journal:  J Biol Chem       Date:  2011-05-09       Impact factor: 5.157

2.  Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes.

Authors:  Caitrin W McDonough; Yan Gong; Sandosh Padmanabhan; Ben Burkley; Taimour Y Langaee; Olle Melander; Carl J Pepine; Anna F Dominiczak; Rhonda M Cooper-Dehoff; Julie A Johnson
Journal:  Hypertension       Date:  2013-05-20       Impact factor: 10.190

3.  Spatial N-glycomics of the human aortic valve in development and pediatric endstage congenital aortic valve stenosis.

Authors:  Peggi M Angel; Richard R Drake; Yeonhee Park; Cassandra L Clift; Connor West; Savanna Berkhiser; Gary Hardiman; Anand S Mehta; David P Bichell; Yan Ru Su
Journal:  J Mol Cell Cardiol       Date:  2021-01-29       Impact factor: 5.000

Review 4.  Molecular diversity and evolution of the Siglec family of cell-surface lectins.

Authors:  Takashi Angata
Journal:  Mol Divers       Date:  2006-11       Impact factor: 3.364

Review 5.  Possible Influences of Endogenous and Exogenous Ligands on the Evolution of Human Siglecs.

Authors:  Takashi Angata
Journal:  Front Immunol       Date:  2018-12-04       Impact factor: 7.561

6.  Exploring disease-specific methylated CpGs in human male genital abnormalities by using methylated-site display-amplified fragment length polymorphism (MSD-AFLP).

Authors:  Toshiki Aiba; Toshiyuki Saito; Akiko Hayashi; Shinji Sato; Harunobu Yunokawa; Maki Fukami; Yutaro Hayashi; Kentaro Mizuno; Yuichi Sato; Yoshiyuki Kojima; Seiichiroh Ohsako
Journal:  J Reprod Dev       Date:  2019-08-29       Impact factor: 2.214

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.